YG

Yourgene Health PLCLSE Yourgene Health Stock Report

Last reporting period 30 Sep, 2022

Updated —

Last price

Market cap $B

0.022

Micro

Exchange

XLON - London Stock Exchange

YGEN.L Stock Analysis

YG

Uncovered

Yourgene Health PLC is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-34/100

Low score

Market cap $B

0.022

Dividend yield

Shares outstanding

3 176.96 B

Yourgene Health Plc engages in the development and commercialization of genomic services and technologies. The firm primarily develops, manufactures, and commercializes molecular diagnostic solutions for reproductive health, precision medicine and infectious diseases. The Company’s segments include Genomic Technologies segment provides the in vitro diagnostic products, software and instrumentation, and Genomic Services segment provide services to clinicians, third party clinical service providers and contract research organizations. The Company’s flagship in vitro diagnostic products include non-invasive prenatal tests for Down’s Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests and DPYD genotyping. The firm has a range of deoxyribonucleic (DNA) sample preparation platforms, powered by Ranger Technology, the Yourgene LightBench and Yourgene QS250, ideal for cell-free DNA applications in non-invasive prenatal tests and oncology including liquid biopsy.

View Section: Eyestock Rating